{"prompt": "['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', '12 REFERENCES', '1.', 'Sundy J. S., Becker M. A., Baraf H. S., Barkhuizen A., Moreland L. W., Huang W., Waltrip R. W., 2nd, Maroli A. N., Horowitz Z.', 'Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated', 'uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 2008;58(9):2882-', '91. 10.1002/art.23810.', '2.', 'Administration Food and Drug.AAC Briefing Document Krystexxa', '(Pegloticase).2009.http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisDr', 'sAdvisoryCommittee/UCM165714.pdf.. March 23, 2016', '3.', 'Administration Food and Drug.KRYSTEXXA\u2122 (pegloticase) for intravenous infusion BLA No. 125293', '2009.http://tinyurl.com/j293s5h.', '4.', 'Baraf H. S., Matsumoto A. K., Maroli A. N., Waltrip R. W., 2nd. Resolution of gouty tophi after twelve weeks of pegloticase', 'treatment. Arthritis Rheum. 2008;58(11):3632-4. 10.1002/art.23993', '5.', 'Sundy J. S., Baraf H.S., Yood R. A., Edwards N.L., Gutierrez-Urena S. R., Treadwell E. L., Vazquez-Mellado J., White W. B.,', 'Lipsky P. E., Horowitz Z., Huang W., Maroli A. N., Waltrip R. W., 2nd, Hamburger S. A., Becker M. A. Efficacy and tolerability', 'of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized', 'controlled trials. JAMA. 2011;306(7):711-20. 10.1001/jama.2011.1169.', '6.', 'Hershfield M. S., Ganson N. J., Kelly S.J., Scarlett E. L., Jaggers D. A., Sundy J. S. Induced and pre-existing anti-polyethylene', 'glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients.', 'Arthritis Res Ther. 2014;16(2):R63. 10.1186/ar4500. 4060462', '7.', 'Singh J. A., Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare', 'utilisation in US veterans. Ann Rheum Dis. 2008;67(9):1310-6 10.1136/ard.2007.081604.', '8.', 'Sattui S. E., Singh J. A., Gaffo A. L. Comorbidities in patients with crystal diseases and hyperuricemia. Rheum Dis Clin North', 'Am. 2014;40(2):251-78. 10.1016/j.rdc.2014.01.005. Pmc4159668', '9.', 'Zhu Y., Pandya B. J., Choi H. K. Prevalence of gout and hyperuricemia in the US general population: the National Health and', 'Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136-41. 10.1002/art.30520.', '10.', 'Saag K. G., Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther. 2006;8 Suppl 1:S2.', '10.1186/ar1907. Pmc3226107', '11.', 'Mikuls T. R., Farrar J. T., Bilker W. B., Fernandes S., Schumacher H. R., Jr., Saag K. G. Gout epidemiology: results from the UK', 'General Practice Research Database, 1990-1999. Ann Rheum Dis. 2005;64(2):267-72.10.1136/ard.2004.024091', 'Pmc1755343', '12.', 'Roddy Edward, Doherty Michael. Gout. Epidemiology of gout. Arthritis Research & Therapy. 2010;12(6):223-', '10.1186/ar3199.', '13.', 'Wertheimer Albert, Morlock Robert, Becker Michael A. A Revised Estimate of the Burden of Illness of Gout. Current', 'Therapeutic Research. 2013;75:1-4.http://dx.doi.org/10.1016/j.curtheres.2013.04.003', '14.', 'Brook R. A., Forsythe A., Smeeding J. E., Lawrence Edwards N. Chronic gout: epidemiology, disease progression, treatment', 'and disease burden. Curr Med Res Opin. 2010;26(12):2813-21. 10.1185/03007995.2010.533647.', '15.', 'Khanna P., Khanna D., Storgard C., Baumgartner S., Morlock R. A world of hurt: failure to achieve treatment goals in', 'patients with gout requires a paradigm shift. Postgrad Med. 2016;128(1):34-40 10.1080/00325481.2016.1113840', '16.', 'Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2005;20 Suppl', '6:vi3-9. 10.1093/ndt/gfh1092.', '17.', 'Lipsky Peter E., Calabrese Leonard H., Kavanaugh Arthur, Sundy John S., Wright David, Wolfson Marsha, Becker Michael A.', 'Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory', 'chronic gout. Arthritis Research & Therapy. 2014;16(2):R60-R. 10.1186/ar4497.', '18.', 'Baraf H. S., Yood R. A., Ottery F. D., Sundy J. S., Becker M. A. Infusion-related reactions with pegloticase, a recombinant', 'uricase for the treatment of chronic gout refractory to conventional therapy. J Clin Rheumatol. 2014;20(8):427-32', '10.1097/rhu.0000000000000200. Pmc4280274', '19.', 'Baraf Herbert S. B., Becker Michael A., Gutierrez-Urena Sergio R., Treadwell Edward L., Vazquez-Mellado Janitzia, Rehrig', 'Claudia D., Ottery Faith D., Sundy John S., Yood Robert A. Tophus burden reduction with pegloticase: results from phase 3', 'randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis', 'Research & Therapy. 2013;15(5):R137-R. 10.1186/ar4318.', '20.', 'Becker M. A., Schumacher H. R., Benjamin K. L., Gorevic P., Greenwald M., Fessel J., Edwards L., Kawata A. K., Frank L.,', 'Waltrip R., Maroli A., Huang B., Sundy J. S. Quality of life and disability in patients with treatment-failure gout. J Rheumatol.', '2009;36(5):1041-8 10.3899/jrheum.071229.', '21.', 'Hershfield M. S., Roberts L. J., 2nd, Ganson N. J., Kelly S. J., Santisteban I., Scarlett E., Jaggers D., Sundy J. S. Treating gout', 'with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. Proc', '46']\n\n###\n\n", "completion": "END"}